The classification of skin disease severity (0%, >0% to 3%, >3%) by joint involvement (low vs moderate-high)
| BSA | ||||||
| 0% | >0% to 3% | >3% | Total | P value | Cramer’s V | |
| All patients | ||||||
| CDAI | ||||||
| Low | 258 | 447 | 256 | 961 | ||
| Moderate/high | 109 | 227 | 245 | 581 | ||
| Total | 367 | 674 | 501 | 1542 | <0.001 | 0.1639 |
| OR (95% CI) | Reference | 1.20 (0.91, 1.58) | 2.27 (1.71, 3.01) | |||
| No DMARD therapy at enrolment | ||||||
| CDAI | ||||||
| Low | 29 | 54 | 36 | 119 | ||
| Moderate/high | 13 | 61 | 73 | 147 | ||
| Total | 42 | 115 | 109 | 266 | <0.001 | 0.2477 |
| OR (95% CI) | Reference | 2.52 (1.19, 5.33) | 4.52 (2.10, 9.73) | |||
| csDMARDs only at enrolment | ||||||
| CDAI | ||||||
| Low | 60 | 134 | 71 | 265 | ||
| Moderate/high | 30 | 68 | 67 | 165 | ||
| Total | 90 | 202 | 138 | 430 | 0.012 | 0.1439 |
| OR (95% CI) | Reference | 1.01 (0.60, 1.72) | 1.89 (1.09, 3.27) | |||
| Biologic or tsDMARDs at enrolment | ||||||
| CDAI | ||||||
| Low | 156 | 240 | 145 | 541 | ||
| Moderate/high | 60 | 92 | 95 | 247 | ||
| Total | 216 | 332 | 240 | 788 | 0.004 | 0.1175 |
| OR (95% CI) | Reference | 1.00 (0.68, 1.46) | 1.70 (1.15, 2.52) | |||
Drug therapy was missing for 58 patients. P value for χ2 test of association.
BSA, body surface area; CDAI, Clinical Disease Activity Index; DMARD, disease-modifying antirheumatic drug; OR, odds ratio; csDMARD, conventional synthetic DMARD; tsDMARD, targeted synthetic DMARD.